Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused ...

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio ...

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

The CKD Anemia market in 7MM offers growth opportunities due to rising diagnosed cases, unmet clinical needs, and a promising late-stage pipeline. Strategic partnerships and in-licensing could ...

Modus Therapeutics Holding AB (“Modus”) today announces that the first patient has been dosed in Part 2 of the company’s ongoing Phase IIa clinical study evaluating sevuparin for the treatment of ...

(MENAFN- GlobeNewsWire - Nasdaq) The CKD Anemia market in 7MM offers growth opportunities due to rising diagnosed cases, unmet clinical needs, and a promising late-stage pipeline. Strategic ...

Women with low hemoglobin and nondialysis CKD, left untreated, have a higher risk for major adverse cardiovascular risks than men. Anemia of chronic kidney disease (CKD) increases risks of major ...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan ...

Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs December 7, 2025 ...